Esther Rajavelu
Stock Analyst at UBS
(0.94)
# 3,851
Out of 5,182 analysts
23
Total ratings
54.55%
Success rate
-10.31%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Esther Rajavelu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Neutral | $45 → $46 | $72.23 | -36.31% | 4 | Aug 12, 2025 | |
| DNLI Denali Therapeutics | Maintains: Buy | $70 → $32 | $19.94 | +60.48% | 2 | Apr 9, 2024 | |
| ALNY Alnylam Pharmaceuticals | Upgrades: Buy | $141 → $215 | $308.51 | -30.31% | 5 | Oct 4, 2021 | |
| RARE Ultragenyx Pharmaceutical | Initiates: Sell | $73 | $23.99 | +204.29% | 1 | Aug 19, 2021 | |
| BHVN Biohaven | Downgrades: Neutral | $108 → $109 | $9.59 | +1,036.60% | 6 | Aug 10, 2021 | |
| STOK Stoke Therapeutics | Initiates: Neutral | $35 | $33.71 | +3.83% | 1 | May 18, 2021 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $174 → $228 | $201.22 | +13.31% | 1 | Mar 1, 2021 | |
| ARWR Arrowhead Pharmaceuticals | Initiates: Perform | n/a | $73.60 | - | 1 | Dec 13, 2019 | |
| INVA Innoviva | Initiates: Hold | $13 | $23.36 | -44.35% | 1 | Nov 20, 2017 | |
| TXMD TherapeuticsMD | Initiates: Buy | $10 | $2.07 | +383.09% | 1 | Jul 21, 2017 |
Ionis Pharmaceuticals
Aug 12, 2025
Maintains: Neutral
Price Target: $45 → $46
Current: $72.23
Upside: -36.31%
Denali Therapeutics
Apr 9, 2024
Maintains: Buy
Price Target: $70 → $32
Current: $19.94
Upside: +60.48%
Alnylam Pharmaceuticals
Oct 4, 2021
Upgrades: Buy
Price Target: $141 → $215
Current: $308.51
Upside: -30.31%
Ultragenyx Pharmaceutical
Aug 19, 2021
Initiates: Sell
Price Target: $73
Current: $23.99
Upside: +204.29%
Biohaven
Aug 10, 2021
Downgrades: Neutral
Price Target: $108 → $109
Current: $9.59
Upside: +1,036.60%
Stoke Therapeutics
May 18, 2021
Initiates: Neutral
Price Target: $35
Current: $33.71
Upside: +3.83%
Jazz Pharmaceuticals
Mar 1, 2021
Maintains: Buy
Price Target: $174 → $228
Current: $201.22
Upside: +13.31%
Arrowhead Pharmaceuticals
Dec 13, 2019
Initiates: Perform
Price Target: n/a
Current: $73.60
Upside: -
Innoviva
Nov 20, 2017
Initiates: Hold
Price Target: $13
Current: $23.36
Upside: -44.35%
TherapeuticsMD
Jul 21, 2017
Initiates: Buy
Price Target: $10
Current: $2.07
Upside: +383.09%